Molecular testing in lung cancer: The time is now

Current Oncology Reports

Volumn 12, Issue 5, 2010, Pages 335-348

  Cheng, Haiying ^a   Xu, Xunhai ^a   Costa, Daniel B ^b   Powell, Charles A ^a   Halmos, Balazs ^a  

^a Department of Medicine   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Biomarkers; EGFR; EML4 ALK translocation; KRAS; Molecular testing; Non small cell lung cancer

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; ANAPLASTIC LYMPHOMA KINASE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; K RAS PROTEIN; MESENCHYMAL EPITHELIAL TRANSITION FACTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MET; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NAVELBINE; PEMETREXED; PLACEBO; PROTEIN EML4; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1; SCATTER FACTOR RECEPTOR; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 184; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; TUMOR MARKER;

ANTIANGIOGENIC THERAPY; CANCER CLASSIFICATION; CANCER RESISTANCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COPY NUMBER VARIATION; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TRANSLOCATION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PHARMACOGENOMICS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); GENETICS; LUNG NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77956266461     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0118-z     Document Type: Review

References (86)

1. R Arriagada B Bergman A Dunant, et al. 2004 Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 351 360 10.1056/NEJMoa031644 14736927
2. T Winton R Livingston D Johnson, et al. 2005 Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2589 2597 10.1056/NEJMoa043623 1:CAS:528:DC%2BD2MXls1Wqurg%3D 15972865
3. RJ Slebos RE Kibbelaar O Dalesio, et al. 1990 K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 561 565 1:STN:280:DyaK3czktVemsQ%3D%3D 2199829
4. C Mascaux N Iannino B Martin, et al. 2005 The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 131 139 10.1038/sj.bjc.6602258 1:CAS:528:DC%2BD2MXhtFSjsrs%3D 15597105
5. CA Butts K Ding L Seymour, et al. 2010 Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10 J Clin Oncol 28 29 34 10.1200/JCO.2009.24.0333 1:CAS:528:DC%2BC3cXhtF2ku7s%3D 19933915
6. Y Horio T Takahashi T Kuroishi, et al. 1993 Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer Cancer Res 53 1 4 1:CAS:528:DyaK3sXnvValtg%3D%3D 8380124
7. L Cheng MR Spitz WK Hong Q Wei 2000 Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis Carcinogenesis 21 1527 1530 10.1093/carcin/21.8.1527 1:CAS:528: DC%2BD3cXlvVeqsbY%3D 10910954
8. GR Simon S Sharma A Cantor, et al. 2005 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Chest 127 978 983 10.1378/chest.127.3.978 15764785
9. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 991 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D 16957145
10. Z Zheng T Chen X Li, et al. 2007 DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl J Med 356 800 808 10.1056/NEJMoa065411 1:CAS:528:DC%2BD2sXhvFKltLs%3D 17314339
11. G Bepler S Sharma A Cantor, et al. 2004 RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer J Clin Oncol 22 1878 1885 10.1200/JCO.2004.12.002 1:CAS:528:DC%2BD2cXptlCksr0%3D 15143080
12. AC Borczuk RL Toonkel CA Powell 2009 Genomics of lung cancer Proc Am Thorac Soc 6 152 158 10.1513/pats.200807-076LC 1:CAS:528:DC%2BD1MXltlOqt7s%3D 19349483
13. A Potti S Mukherjee R Petersen, et al. 2006 A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer N Engl J Med 355 570 580 10.1056/NEJMoa060467 1:CAS:528:DC%2BD28XotVKnu7g%3D 16899777
14. K Shedden JM Taylor SA Enkemann, et al. 2008 Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study Nat Med 14 822 827 10.1038/nm.1790 1:CAS:528:DC%2BD1cXptlKltr8%3D 18641660
15. GV Scagliotti P Parikh J von Pawel, et al. 2008 Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543 3551 10.1200/JCO.2007.15.0375 1:CAS:528:DC%2BD1cXpvVWmtLg%3D 18506025 This phase 3 study demonstrated that in patients with adenocarcinoma and large cell histology, overall survival was superior for cisplatin/pemetrexed versus cisplatin/gemcitabine compared to patients with squamous cell histology, for whom the opposite results were seen
16. G Scagliotti N Hanna F Fossella, et al. 2009 The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies Oncologist 14 253 263 10.1634/theoncologist.2008-0232 1:CAS:528: DC%2BD1MXltFektrc%3D 19221167
17. T Ciuleanu T Brodowicz C Zielinski, et al. 2009 Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 1432 1440 10.1016/S0140-6736(09)61497-5 1:CAS:528:DC%2BD1MXhtlSru7jL 19767093
18. T Takenaka I Yoshino H Kouso, et al. 2007 Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer Int J Cancer 121 895 900 10.1002/ijc.22738 1:CAS:528:DC%2BD2sXotlequ7k%3D 17417781
19. K Azuma T Sasada A Kawahara, et al. 2009 Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel Lung Cancer 64 326 333 10.1016/j.lungcan.2008.09.002 18977553
20. RV Lord J Brabender D Gandara, et al. 2002 Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2286 2291 1:CAS:528: DC%2BD38XmtVWhsLw%3D 12114432
21. M Cobo D Isla B Massuti, et al. 2007 Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 2747 2754 10.1200/JCO.2006.09.7915 1:CAS:528:DC%2BD2sXosValtLk%3D 17602080
22. G Bepler I Kusmartseva S Sharma, et al. 2006 RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer J Clin Oncol 24 4731 4737 10.1200/JCO.2006.06.1101 1:CAS:528:DC%2BD28XhtFynsr3K 16966686
23. R Rosell KD Danenberg V Alberola, et al. 2004 Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 1318 1325 10.1158/1078-0432.CCR-03-0156 1:CAS:528:DC%2BD2cXhsVCqu7o%3D 14977831
24. E Giovannetti V Mey S Nannizzi, et al. 2005 Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells Mol Pharmacol 68 110 118 1:CAS:528: DC%2BD2MXlvVSqtbc%3D 15795320
25. G Bepler KE Sommers A Cantor, et al. 2008 Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer J Thorac Oncol 3 1112 1118 10.1097/JTO.0b013e3181874936 18827606
26. G Simon A Sharma X Li, et al. 2007 Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer J Clin Oncol 25 2741 2746 10.1200/JCO.2006.08.2099 1:CAS:528: DC%2BD2sXosValtLg%3D 17602079
27. FR Hirsch M Varella-Garcia F Cappuzzo 2009 Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer Oncogene 28 Suppl 1 S32 S37 10.1038/onc.2009.199 1:CAS:528:DC%2BD1MXpvFCrsrc%3D 19680294
28. T John G Liu MS Tsao 2009 Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors Oncogene 28 Suppl 1 S14 S23 10.1038/onc.2009.197 1:CAS:528: DC%2BD1MXpvFCktb4%3D 19680292
29. VA Miller MG Kris N Shah, et al. 2004 Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer J Clin Oncol 22 1103 1109 10.1200/JCO.2004.08.158 1:CAS:528:DC%2BD2cXptlCku7g%3D 15020612
30. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D 15118073
31. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D 15118125
32. M Tokumo S Toyooka K Kiura, et al. 2005 The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 1167 1173 1:CAS:528: DC%2BD2MXht1ynt7c%3D 15709185
33. RS Leidner P Fu B Clifford, et al. 2009 Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer J Clin Oncol 27 5620 5626 10.1200/JCO.2009.23.1431 1:CAS:528:DC%2BC3cXhtVWit7k%3D 19786660
34. SV Sharma DW Bell J Settleman DA Haber 2007 Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 169 181 10.1038/nrc2088 1:CAS:528:DC%2BD2sXitVGrsbo%3D 17318210
35. DA Eberhard BE Johnson LC Amler, et al. 2005 Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 5900 5909 10.1200/JCO.2005.02.857 1:CAS:528:DC%2BD2MXhtVKgtbzO 16043828
36. CQ Zhu G da Cunha Santos K Ding, et al. 2008 Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 4268 4275 10.1200/JCO.2007.14. 8924 1:CAS:528:DC%2BD1cXhtF2it7bF 18626007
37. IJ Dahabreh H Linardou F Siannis, et al. 2010 Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 16 291 303 10.1158/1078-0432.CCR-09-1660 1:CAS:528:DC%2BC3cXot1Sh 20028749
38. TS Mok YL Wu S Thongprasert, et al. 2009 Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947 957 10.1056/NEJMoa0810699 1:CAS:528:DC%2BD1MXhtVygsbfK 19692680 The I-PASS study showed that gefitinib is superior to carboplatin-paclitaxel as first-line treatment in Asian patients with advanced lung adenocarcinoma and no/limited smoking history. PFS was significantly longer for EGFR-mutant tumors when treated with gefitinib versus chemotherapy, while the opposite held true for EGFR wild-type tumors
39. T Mitsudomi S Morita Y Yatabe, et al. 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 121 128 10.1016/S1470-2045(09)70364-X 1:CAS:528:DC%2BC3cXhtlGgtbo%3D 20022809
40. JY Douillard FA Shepherd V Hirsh, et al. 2010 Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 744 752 10.1200/JCO.2009.24.3030 1:CAS:528:DC%2BC3cXksVyrsbY%3D 20038723 The INTEREST trial showed that patients with EGFR-mutated tumors had longer PFS with gefitinib versus docetaxel in the second-line setting
41. • Cappuzzo TC, Stelmakh L, Cicenas S, et al.: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 2009, 27(15s): abstract 8001. In the phase 3 SATURN trial, erlotinib was shown to produce prolonged PFS and overall survival when compared with placebo in the maintenance setting after first-line chemotherapy. The benefit was modest overall but very striking in patients with EGFR-mutant tumors.
42. S Khambata-Ford CT Harbison LL Hart, et al. 2010 Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer J Clin Oncol 28 918 927 10.1200/JCO.2009.25.2890 1:CAS:528: DC%2BC3cXktF2lsbY%3D 20100958
43. S Kobayashi TJ Boggon T Dayaram, et al. 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786 792 10.1056/NEJMoa044238 1:CAS:528:DC%2BD2MXhsFCiurk%3D 15728811
44. W Pao VA Miller KA Politi, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73 10.1371/journal.pmed.0020073 15737014
45. PS Hammerman PA Janne BE Johnson 2009 Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 15 7502 7509 10.1158/1078-0432.CCR-09-0189 1:CAS:528: DC%2BD1MXhsFGgurrN 20008850
46. W Zhou D Ercan L Chen, et al. 2009 Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 1070 1074 10.1038/nature08622 1:CAS:528:DC%2BD1MXhs1SktbvI 20033049
47. S Maheswaran LV Sequist S Nagrath, et al. 2008 Detection of mutations in EGFR in circulating lung-cancer cells N Engl J Med 359 366 377 10.1056/NEJMoa0800668 1:CAS:528:DC%2BD1cXovFSqtbc%3D 18596266
48. LE Coate T John MS Tsao FA Shepherd 2009 Molecular predictive and prognostic markers in non-small-cell lung cancer Lancet Oncol 10 1001 1010 10.1016/S1470-2045(09)70155-X 1:CAS:528:DC%2BD1MXhtFOqurjE 19796752
49. F Cappuzzo FR Hirsch E Rossi, et al. 2005 Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643 655 10.1093/jnci/dji112 1:CAS:528: DC%2BD2MXjvFymt70%3D 15870435
50. R Pirker JR Pereira A Szczesna, et al. 2009 Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525 1531 10.1016/S0140-6736(09)60569-9 1:CAS:528:DC%2BD1MXltlaqurs%3D 19410716
51. FR Hirsch M Varella-Garcia PA Bunn Jr, et al. 2006 Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 5034 5042 10.1200/JCO.2006.06.3958 1:CAS:528:DC%2BD28Xht1GnurzF 17075123
52. DA Eberhard G Giaccone BE Johnson 2008 Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting J Clin Oncol 26 983 994 10.1200/JCO.2007.12.9858 18281673
53. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 1160 1174 10.1056/NEJMra0707704 1:CAS:528:DC%2BD1cXjt1ahsL4%3D 18337605
54. F Taguchi B Solomon V Gregorc, et al. 2007 Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study J Natl Cancer Inst 99 838 846 10.1093/jnci/djk195 1:CAS:528:DC%2BD2sXns1als7o%3D 17551144
55. JM Amann JW Lee H Roder, et al. 2010 Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503 J Thorac Oncol 5 169 178 10.1097/JTO.0b013e3181c8cbd9 20035238
56. Carbone DP, Salmon JS, Billheimer D, et al.: VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009 Dec 24 (Epub ahead of print).
57. W Pao TY Wang GJ Riely, et al. 2005 KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 e17 10.1371/journal.pmed.0020017 15696205
58. H Linardou IJ Dahabreh D Kanaloupiti, et al. 2008 Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 962 972 10.1016/S1470-2045(08)70206-7 1:CAS:528:DC%2BD1cXhtFOmurvJ 18804418
59. M Soda YL Choi M Enomoto, et al. 2007 Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 561 566 10.1038/nature05945 1:CAS:528:DC%2BD2sXosVSrtrs%3D 17625570 This study identified the most recent oncogene found in NSCLC, EML4-ALK fusion gene
60. K Rikova A Guo Q Zeng, et al. 2007 Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 131 1190 1203 10.1016/j.cell.2007.11.025 1:CAS:528:DC%2BD1cXksFGnsQ%3D%3D 18083107
61. K Takeuchi YL Choi Y Togashi, et al. 2009 KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer Clin Cancer Res 15 3143 3149 10.1158/1078-0432.CCR-08- 3248 1:CAS:528:DC%2BD1MXltFOrtbY%3D 19383809
62. YL Choi K Takeuchi M Soda, et al. 2008 Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer Cancer Res 68 4971 4976 10.1158/0008-5472.CAN-07-6158 1:CAS:528:DC%2BD1cXnvFOqsbY%3D 18593892
63. M Soda S Takada K Takeuchi, et al. 2008 A mouse model for EML4-ALK-positive lung cancer Proc Natl Acad Sci U S A 105 19893 19897 10.1073/pnas.0805381105 1:CAS:528:DC%2BD1cXhsFCmtb7F 19064915
64. L Horn W Pao 2009 EML4-ALK: honing in on a new target in non-small-cell lung cancer J Clin Oncol 27 4232 4235 10.1200/JCO.2009.23.6661 1:CAS:528:DC%2BD1MXht1WisbvE 19667260
65. K Inamura K Takeuchi Y Togashi, et al. 2008 EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 13 17 10.1097/JTO.0b013e31815e8b60 18166835
66. SJ Rodig M Mino-Kenudson S Dacic, et al. 2009 Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population Clin Cancer Res 15 5216 5223 10.1158/1078-0432.CCR-09-0802 1:CAS:528:DC%2BD1MXpvFeitrY%3D 19671850
67. AT Shaw BY Yeap M Mino-Kenudson, et al. 2009 Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 4247 4253 10.1200/JCO.2009.22.6993 1:CAS:528:DC%2BD1MXht1WisbvF 19667264
68. JP Koivunen C Mermel K Zejnullahu, et al. 2008 EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin Cancer Res 14 4275 4283 10.1158/1078-0432.CCR-08-0168 1:CAS:528:DC%2BD1cXnvFyks7s%3D 18594010
69. U McDermott AJ Iafrate NS Gray, et al. 2008 Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res 68 3389 3395 10.1158/0008-5472.CAN-07-6186 1:CAS:528:DC%2BD1cXltlSlsbg%3D 18451166
70. CD Shaw AT AJ Iafrate BJ Dezube, et al. 2009 Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations J Thorac Oncol 4 S305 S306
71. L Toschi PA Janne 2008 Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer Clin Cancer Res 14 5941 5946 10.1158/1078-0432.CCR-08-0071 1:CAS:528: DC%2BD1cXhtF2nur3E 18829470
72. L Faoro GM Cervantes E El-Hashani R Salgia 2009 MET receptor tyrosine kinase J Thorac Oncol 4 S1064 S1065 10.1097/01.JTO.0000361752.86918.09 19861919
73. F Cappuzzo A Marchetti M Skokan, et al. 2009 Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 1667 1674 10.1200/JCO.2008.19.1635 19255323
74. F Cappuzzo PA Janne M Skokan, et al. 2009 MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients Ann Oncol 20 298 304 10.1093/annonc/mdn635 1:STN:280: DC%2BD1M7jtlWlsg%3D%3D 18836087
75. JA Engelman K Zejnullahu T Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 10.1126/science.1141478 1:CAS:528:DC%2BD2sXltlOjt7g%3D 17463250
76. AB Turke K Zejnullahu YL Wu, et al. 2010 Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC Cancer Cell 17 77 88 10.1016/j.ccr.2009.11.022 1:CAS:528:DC%2BC3cXkvFKgs7Y%3D 20129249
77. KS Nguyen S Kobayashi DB Costa 2009 Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway Clin Lung Cancer 10 281 289 10.3816/CLC.2009.n.039 1:CAS:528:DC%2BD1MXhtVSms7bO 19632948
78. Arqule Joins the Phase III Club. http://seekingalpha.com/article/198568- arqule-joins-the-phase-iii-club. Accessed April 13, 2010.
79. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI 17167137
80. Reck M, von Pawel J, Zatloukal P, et al.: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010 Feb 11 (Epub ahead of print).
81. A Dowlati R Gray AB Sandler, et al. 2008 Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study Clin Cancer Res 14 1407 1412 10.1158/1078-0432.CCR-07-1154 1:CAS:528:DC%2BD1cXislSrs7c%3D 18316562
82. N Murukesh C Dive GC Jayson 2010 Biomarkers of angiogenesis and their role in the development of VEGF inhibitors Br J Cancer 102 8 18 10.1038/sj.bjc.6605483 1:CAS:528:DC%2BC3cXhtFOltA%3D%3D 20010945
83. SE Dahlberg AB Sandler JR Brahmer, et al. 2010 Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 949 954 10.1200/JCO.2009.25.4482 1:CAS:528: DC%2BC3cXktF2ltr8%3D 20085937
84. BATTLE Trial Personalizes Lung Cancer Therapy [AACR press release]. April 18, 2010.
85. WD Travis N Rekhtman GJ Riley, et al. 2010 Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift J Thorac Oncol 5 411 414 10.1097/JTO.0b013e3181d57f6e 20357614
86. A Marchetti M Milella L Felicioni, et al. 2009 Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones Neoplasia 11 1084 1092 1:CAS:528:DC%2BD1MXhtFKrsb7I 19794967